hplc ready to use diagnostic kit for hplc

HPLC

READYTOUSEDIAGNOSTICKIT

FORHPLCPresenta:on2017

Ermes|Cas:glioni|ERRECI

ERRECILIFESCIENCECHEMICALCLINICALAREA

l  WEAREMANUFACTURERSOFDIAGNOSTICREADYTOUSEHPLCKIT

l  ERRECIworksinscien:ficinstrumenta:onmarketfrom1985,concerningchemicalclinicalareawearehistorical partner of BIOCHROM Ltd (part of Harvard Bioscience) with par:cular reference of AAA(automa:caminoacidsanalyzer)involvedinnewbornsscreeningformetabolicdiseases;

l  The panel kit cover determina:on in several area that include occupa:onal medicine, metabolicdisease, drugsmonitoring, oxida:ve stress, vitamins profile, osteoporosis, diabetes, biogenic amines,etc. It’s include technical andapplica:ve support;Our kits are compa:blewith all principal brandofHPLCproducer

l  ERRECI can supply alsoOEM“open andmodular”HPLC systems, our laboratories use this system todevelopeandtestourkits,anywayourHPLCsystemiscompa:blewithallanaly:calmethodandotherkitavailableonthemarket.

l  Youcanobtainmoredetailsonwww.erreci-tech.com

APPLICATIONAREAS

l  DIABETES&THALASSEMIA

l  METABOLICDISEASE

l  BIOGENICAMINES

l  DRUGSMONITORING

l  OSTEOPOROSIS

l  BIOMONITORING

l  OCCUPATIONALMEDICINE

l  VITAMINPROFILING

ANALITYCALTECHNIQUES

l  LiquidChromatography(HPLC);Isocra:candGradient(MadeinGermania)

l  DetectorUV/VIS,DAD,Spectrofluorimetric,Amperometric,Refrac:veIndex,Conduc:meter

l  Automa:c sample prepara:on is available with specific instruments for HPLC, to allowmore produc:vity andsimplifyworksforusers,it’smoresafetyandreducepoten:alerrorsofmanualprepara:on

•  CEmark kitswithmobilephase, internal standard, calibrator;whennecessary:deriva:zing,deproteinizing,washsolu:on,SPEandallisnecessarytoperforms100/200/500Tests(dependingonkit)

•  ColumOvenwithdevia:onvalvetoallowautoma:cselec:onofproperlycolumntoanyanaly:calparameter

•  Workingflowpar:cular low,typical from0.6to0.7 l/min.Lowconsump:onofeluentstoreducecostofanalysisanddisposalodsolvents

•  Highresolu:onanaly:calcolumn,FASTop:on

•  Simplyrapidmethod

•  Availablesampleprepara:oninstrumenttoop:mizepre-analy:caltreatment

•  Amperometricandelectrochemicaldetectoraren’tnecessary(availableonrequest)

SPECIALFEATURES

ONECOMPANYFORHPLCANDDIAGNOSTICKIT

•  Isocra:corGradientHPLCsystems(LPGoHPG)

•  AutosamplerOp:onwithorwithoutthermostata:on

•  Automa:ccolumnovenwithselec:onvalvetochoiceautoma:callycolumnsforeveryanaly:calparameters

•  Detectors;UV/VIS,DAD,Fluorescence,Refrac:onIndex

•  Amperometricand/orCoulmeterDetectorarenotnecessarybutavailableonrequest

KITACTUALLYAVAILABLECODICE Metodo DESCRIPTION Test RC-HPB-K00500 UV/Vis Pathological hemoglobin variants in blood samples 500 RC-EGB-K00500 UV/Vis Glycated Hemoglobin in blood samples 500 RC-5HU-K00100 FL 5-HIAA 5-hydroxyindoleacetic acid in urine samples 100 RC-VMU-K00100 FL VMA (vanillylmandelic acid) in urine samples 100

RC-TRU-K00100 FL (VMA/5-HIAA/HVA) Vanillylmandelic acid (VMA), 5-hydroxyindoleacetic acid (5-HIAA), Homovanillic acid (HVA) in urine sample

100

RC-SEU-K00100 FL Serotonin in urine samples 100 RC-SES-K00100 FL Serotonin in serum samples 100 RC-CAU-K00100 FL Catecholamines in urine samples 100 RC-MNU-K00100 FL Metanephrine in urine samples 100 RC-CSU-K00100 FL Pyd, Dpd Crosslinks in urine samples 100 RC-ISU-K00100 FL Hydroxyproline in urine samples 100 RC-D3P-K00100 UV/Vis 25-hydroxyvitamin D3 and vitamin D2 in plasma samples 100

KITACTUALLYAVAILABLE

CODICE Metodo DESCRIZIONE Test

RC-AEP-K00100 UV/Vis

AED (Antiepileptic Drugs) in plasma samples or serum Lamotrigine, ethosuximide, primidone, sultiam, 10-hidrosis carbamazepine, phenobarbital, epoxide carbamazepine, oxcarbazepine, carbamazepine and diphenylhydantoin (phenytoin)

100

RC-AE2-K00100 UV/Vis New AED (epilepsy prevention drugs) in plasma or serum samples. IS, zonisamide, lacosamide felbamate, rufinamide 100

RC-LZP-K00100 UV/Vis LEVETIRACETAM in plasma or serum samples 100 RC-AMP-K00100 UV/Vis Amiodarone in plasma or serum 100 RC-VPP-K00100 UV/Vis Valproic acid in plasma samples 100 RC-OMP-0200 FL Homocysteine in serum or plasma samples 100 RC-COU-K00100 UV/Vis Oxalates (oxalic acid) and citrates (citric acid) in urine 100 RC-CTU-K00100 UV/Vis Citrates (citric acid) in urine 100 RC-PTB-K00100 FL Pterins from Blood spot and urine 100

KITACTUALLYAVAILABLE

CODICE Metodo DESCRIZIONE Test RC-TMU-K00100 UV/Vis Acid T,T-muconic acid in urine samples 100

RC-IPP-K00100 UV/Vis Hippuric acid and methyl-hippuric, mandelic acid and phenyl glyoxylic acid in urine samples 100

RC-ACU-K00100 UV/Vis Acetone in urine sample 100 RC-CDT-K00100 UV/Vis CDT (Carbohydrate Deficient Transferrin) in serum or plasma 100 RC-EDU-K00100 UV/Vis 2.5-hexanedione in the urine 100 RC-B6P-K00100 FL Vitamin B6 in Plasma 100 RC-VAS-K00100 UV/Vis Vitamin A / E in serum samples 100 RC-VTC-K00100 UV/Vis Vitamin C in plasma samples 100 RC-SKU-K00100 FL Skatole in urine samples (Dysbiosis) 100 RC-INU-K00100 FL Indicano in urine samples (Dysbiosis) 100 RC-IDU-K00100 FL Indole in urine samples (Dysbiosis) 100

CLINICALDIAGNOSTICDIABETEDIAGNOSISANDTHALASSEMIA(UV/VIS)

l  GLYCATEDHEMOGLOBINEHbF,HbA1c

l  HEMOGLOBINVARIANTS

HbF,HbA2,HbS,HbC,

CLINICALDIAGNOSTICDIABETESANDTHALASSEMIE

l  GLYCATEDHbA1c,HbF;HigherlevelsofHbA1carefoundinpeoplewithpersistentlyelevatedbloodsugar,asindiabetesmellitus.Whilediabe:cpa:enttreatmentgoalsvary,manyincludeatargetrangeofHbA1cvalues.Adiabe:cpersonwithgoodglucosecontrolhasanHbA1clevelthatisclosetoorwithinthereferencerange.TheInterna:onalDiabetesFedera:onandAmericanCollegeofEndocrinologyrecommendHbA1cvaluesbelow6.5%,whileAmericanDiabetesAssocia:onrecommendsthattheHbA1cbebelow7.0%formostpa:ents.

l  VARIANTS;Hemoglobinopathyisakindofgene:cdefectthatresultsinabnormalstructureofoneoftheglobinchainsofthehemoglobinmolecule.Commonhemoglobinopathiesincludesickle-celldiseaseandthalassemia.Thalassemiaisaquan:ta:veproblemoftoofewglobinssynthesized,whereassickle-celldisease(ahemoglobinopathy)isaqualita:veproblemofsynthesisofanon-func:oningglobin.Thalassemiasusuallyresultinunderproduc:onofnormalglobinproteins,okenthroughmuta:onsinregulatorygenes.Hemoglobinopathiesimplystructuralabnormali:esintheglobinproteinsthemselves.Thetwocondi:onsmayoverlap,however,sincesomecondi:onswhichcauseabnormali:esinglobinproteins(hemoglobinopathy)alsoaffecttheirproduc:on(thalassemia).Thus,somethalassemiasarehemoglobinopathies,butmostarenot.Eitherorbothofthesecondi:onsmaycauseanemia

METHABOLICDISEASES

HOMOCYSTEINEINPLASMAORSERUMSAMPLES(FL)

l  HIGH LEVEL OF HOMOCYSTEINE SUGGEST A POTENTIAL RISK OF CARDIOVASCULARDISORDERS

l  HIGH LEVEL OF HOMOCYSTEINE REVEAL RARE EREDITARY DISEASE WHILEHOMOCYSTINURIA

l  THELATTERISQUITECOMMON(ABOUT10%OFTHEWORLDPOPULATION)ANDITISLINKED TO AN INCREASED INCIDENCE OF THROMBOSIS AND CARDIOVASCULARDISEASEANDTHATOCCURSMOREOFTENINPEOPLEWITHABOVEMINIMALLEVELSOFHOMOCYSTEINE

METHABOLICDISEASES

HOMOCYSTEINEINPLASMAORSERUMSAMPLES(FL)

CITRATE(CITRICACID)ANDOXALATE(OXALICACID)INURINE(UV/VIS)

l  CITRATE:CITRATES:IT’SCONSIDEREDONEOFTHEMOSTINTERESTINGURINARYINHIBITORS,CITRATEISTHEMAININHIBITOROFFORMATIONOFKIDNEYSTONES.INURINECITRICACIDINHIBITSTHECRYSTALLIZATIONOFCALCIUM,ITDECREASES,WHENITSCONCENTRATIONINURINEDECREASE,COULDBEARISKFACTORFORFORMATIONOFKIDNEYSTONES.IT’SCONSIDEREDHYPOCITRATURIA,BYCONVENTION,THEURINARYEXCRETIONOFCITRATEBELOW320MG/24HOURS;ITCANBESEPARATEORLINKEDTOOTHERMETABOLICDISEASE.THEMETHODALLOWSTODETERMINETHECONCENTRATIONOFCITRICACID(ALONGOXALICACID)INURINESAMPLES.

l  AREDUCEDURINARYCITRATEEXCRETIONISARISKFACTORFORFORMATIONOFKIDNEYSTONES,INASSOCIATIONWITHANINCREASEDOFEXCRETIONOFCALCIUM,OXALATES,URATES.

METHABOLICDISEASES

Auto-Scaled Chromatogram

AU

-0,004

-0,002

0,000

0,002

0,004

0,006

0,008

0,010

0,012

0,014

0,016

0,018

0,020

0,022

0,024

Minutes2,00 4,00 6,00 8,00 10,00 12,00 14,00 16,00 18,00 20,00

3,37

03,

799

4,11

4ac

ido

citri

co -

4,69

45,

335

6,12

06,

427

8,81

69,

184 10

,148

acid

o os

salic

o - 1

1,54

3

13,5

77

17,6

15

METHABOLICDISEASES

BIOGENICAMINES

l  Catecholaminesinurinesamplesl  Catecholaminesinurinesamples,fastmethodl  Catecholaminesinplasmasamplesl  (VMA/5-HIAA/HVA)Vanillylmandelicacid(VMA)5-Hydroxyindoleace:cacid(5-HIAA),Homovanillicacid(HVA)inurinesample

l  Vanillylmandelicacidinurinesamplesl  5-Hydroxyindoleace:cacidinurinesamplesl  Metanephrinesinurinesamplesl  Serotonininurinesamplesl  Serotonininserumsamples

CATECHOLAMINESINURINESAMPLEl  Catecholamines are chemical compounds derived from the amino acid tyrosinecontaining catechol and amine groups. Some of them are biogenic amines.Catecholamines are water-soluble and are 50% bound to plasma proteins, so theycirculate in the bloodstream. The most abundant catecholamines are epinephrine(adrenaline),norepinephrine(noradrenaline)anddopamine.

l  Catecholamines(norepinephrine,epinephrineanddopamine)areimportantmarkerforthe diagnosis and management of tumor diseases of the sympathoadrenal system.Withthepresentcompletekit thedetermina:onof thecatecholamines isperformedfrom urine. The Kit is characterized by an easy sample prepara:onwith solid phaseextrac:on.Theprovedkitcomponentsensureareliableandtrouble-freeanaly:cs.

BIOGENICAMINESCATECHOLAMINES

CATECHOLAMINES(URINE,FL)


CATECHOLAMINES(PLASMA,FL)


BIOGENICAMINESVMA/5-HIAA/HVA

(VMA/5-HIAA/HVA)VANILLYLMANDELICACID(VMA)5-HYDROXYINDOLEACETICACID(5-HIAA),HOMOVANILLICACID(HVA)IN

URINESAMPLE(FLUORESCENCE)

VMA VANILLYLMANDELIC ACID (URINE, FL); VANILLYLMANDELIC ACID IS A FINALMETABOLITEOFNOREPINEPHRINEANDEPINEPHRINE.5-HIIA (FL);QUANTIFICATIONOF SEROTONIN (URINE) AND ITS PRINCIPALMETABOLITE, 5-HYDROXYINDOLEACETICACIDAREUSEDINDIAGNOSISOFCARCINOIDTUMORDISEASESHVAHOMOVANILLICACID;THEMEASUREMENTOFHVASERVESASASCREENINGTESTFORNEUROBLASTOMAONEOFTHEMOSTCOMMONSOLIDTUMORSOFEARLYCHILDHOOD.

BIOGENICAMINESVMA/5-HIAA/HVA

[min.]Time

0 2 4 6 8 10 12

[a.u.]

Inte

nsity

0

50

100

150

2003.

28

13.

50 V

MA

2

4.35

3

4.93

4

5.28

5

6.17

IS

6

6.72

7

7.23

8

8.38

5HI

AA

9

9.97

1

0

11.0

7 HV

A 1

1

ref_09_05_2016 12_00_52_002 - RF-20A: Channel 1

Result Table (ESTD - ref_09_05_2016 12_00_52_002 - RF-20A: Channel 1)

Reten. Time[min]

Area[a.u..s]

Amount[uL]

CompoundName

Correction Factor

2 3.500 493.203 10.9 VMA 1.000

6 6.167 697.050 1.0 IS 1.000

9 8.383 3345.510 18.1 5HIAA 1.000

11 11.067 435.920 10.6 HVA 1.000

Total 4971.683 40.6

09/05/2016 12:34 Page 2 of 2Chromatogram C:\Clarity\HVA\Data\ref_09_05_2016 12_00_52_002.PRM

l  VANILLYLMANDELIC ACID VMA (URINE, FL); is a metabolite of thecatecholamine: norepinephrine. VMA is found in the urine, along with othercatecholamine metabolites, including homovanillic acid (HVA). In :med urinetests the quan:ty (concentra:on μg /24 h) is assessed, along with crea:nineclearance, and the concentra:on of cor:sols, catecholamines, andmetanephrines. These urinalysis tests are used to diagnose an adrenal glandtumor called pheochromocytoma, a tumor of catecholamine-secre:ngchromaffincells.NorepinephrinebreaksdownintonormetanephrineandVMA.

BIOGENICAMINESVANILLYLMANDELICACIDVMA

Indirizzo: Via delle Robinie, 21 / 20090 - OPERA (MI) / Tel. 02/57600456 - Fax 02/57600082 e-mail: [email protected] web: www.erreci-tech.it Pag. nr. 6

Fluo

resc

ence

0,00

10,00

20,00

30,00

40,00

50,00

60,00

Minutes0,00 1,00 2,00 3,00 4,00 5,00 6,00 7,00 8,00 9,00 10,00 11,00 12,00 13,00 14,00 15,00

2,40

6

3,04

53,

448

3,82

8 VM

A -

5,35

5

7,23

8

IS -

10,0

41

CROMATOGRAMMA!DELLO!STANDARD!DI!CALIBRAZIONE!

CROMATOGRAMMA!CAMPIONE!

DATI!DEL!TEST! Tutti i test sono stati eseguiti utilizzando un sistema HPLC CECIL, così composto: CE4100 Cecil Pompa isocratica per HPLC RF-20 Rivelatore fluorimetrico

Fluo

resc

ence

0,00

10,00

20,00

30,00

40,00

50,00

60,00

Minutes1,00 2,00 3,00 4,00 5,00 6,00 7,00 8,00 9,00 10,00 11,00 12,00 13,00 14,00 15,00

2,33

1

2,97

33,

391

3,65

4

VM

A -

5,25

4

6,42

4

7,02

0

7,65

3

8,42

5

IS -

9,92

4

11,7

22

14,5

7214

,740

BIOGENICAMINESVANILLYLMANDELICACIDVMA

l  5-HIIA (FL);Quan@za@onofurinary5-HIAA is thebest test for carcinoid, but scrupulous caremustbetakenthatspecimencollec@onandpa@[email protected] cause increasedexcre@onof tryptophan, 5-hydroxytryptophanandhistamineaswellasserotonin.Serumserotoninassaymaydetectsomecarcinoidsmissedby5-HIAAassay.The produc@on and metabolism of serotonin is dependent upon the @ssue of origin of thetumor. Tumors from midgut cells, such as ileal carcinoid usually contain and release largequan@@es of serotonin. These amounts may not be fully reflected in the amount of themetabolite (5-HIAA) inurine,because liZle ismetabolized.Tumorsderivedfromforegutcells(bronchial, pancrea@c, duodenal, or biliary carcinoid) produce large amounts of serotonin,whichisoxidizedwithinthetumorto5-HIAA.Withthesetumors,urinaryexcre@onof5-HIAAiso\enmuch higher thanwould be expected from clinical presenta@on. Tumors derived fromhindgutcells(rectalcarcinoid)rarelyproduceexcessserotoninor5-HIAA.

BIOGENICAMINES5-HYDROXYINDOLEACETICACID5-HIAA

BIOGENICAMINES5-HYDROXYINDOLEACETICACID5-HIAA

l Metanephrineisametaboliteofepinephrinecreatedbyac:onofcatechol-Omethyl transferase on pinephrine. With this method the fluorescencedetec:on of the metanephrines normetanephrine, metanephrine and 3-methoxytyramine is free of interferences from tyramine, synephrine andoctopamine. Aker incuba:on, the sample prepara:on simply requires asinglesampleprepara:oncolumnforsplisngofftheconjugate.

BIOGENICAMINESMETANEPHRINES,URINE

BIOGENICAMINESMETANEPHRINES,URINE

l SEROTONIN (FL) is a neurotransmiuer in the central nervoussystem. Serotonin deficiencies are connected with disorderssuch as depression, schizophrenia, and Parkinsons's disease.Moreover,serotoninisproducedinexcessbycarcinoidtumorsThe present complete kit allows the reliable rou:ne HPLCanalysis of serotonin in serum . This kit can assist in theconfirma:onof, e.g., depression, schizophrenia, and carcinoidsyndrome.

BIOGENICAMINESSEROTONIN,SERUM

BIOGENICAMINESSEROTONIN

THERAPEUTICDRUGMONITORING

l AED (UV/VIS)An:epilep:cdrugs inplasmaor serumsamples (8/10An:epilep:c drugs including Lamotrigine). LAMOTRIGINE (UV/VIS)has been successfull in controlling rapid cycling andmixed bipolarstates in people who have not received adequate relief fromlithium, carbamazepine and/or valproate, possibly havingsignificantly more An:- depressant potency than eithercarbamazepineorvalproate.

l New AED (UV/VIS) / New An:epilep:c drugs in plasma or serumsamplesIS,ZONISAMIDE,LACOSAMIDEFELBAMATO,RUFINAMIDE

THERAPEUTICDRUGMONITORING

l VALPROICACIDinplasmasamples(UV/VIS)

l LEVETIRACETAM(UV/VIS)(newAn:epilep:cdrugs)

l AMIODARONE(UV/VIS)Amiodaroneisamemberofanewclassofan:arrhythmicdrugswithpredominantlyClassIII(VaughanWilliams'classifica:on)effectsinplasmaorserum

THERAPEUTICDRUGMONITORINGAEDAn:epilep:cdrugs(UV/VIS)


AU

-0,010

-0,005

0,000

0,005

0,010

0,015

0,020

0,025

0,030

0,035

Minutes1,00 2,00 3,00 4,00 5,00 6,00 7,00 8,00 9,00 10,00 11,00 12,00 13,00

0,98

9et

osuc

cim

mid

e -

1,17

1

prim

idon

e -

1,46

4

carb

dio

lo -

1,8

59

2,37

7D

HC

- 2

,625

feno

barb

ital -

3,0

83

3,53

73,

801

carb

epo

ssid

o -

3,98

0

oxca

rb -

5,1

39

IS -

7,0

21

carb

amaz

epin

a -

10,5

82

feni

toin

a -

11,7

46

A–Profileofan:epile:cdrugswithstandard“ClinCalserumAED2”todose:etosuccimmide,primidone,10-idrossicarbamazepina,fenobarbital,oxcarazepina,carbamazepinaedifenilidantoina(fenitoina).B-Profileofan:epile:cdrugswithstandard“ClinCalserumAED3”AED3todoselamotrigineandetosuccimmide,primidone,sul:am,10-idrossicarbamazepina,fenobarbital,carbamazepinaepossido,oxcarbazepina,carbamazepinaedifenilidantoina(fenitoina).


ELUITIONcalibratoreAED3:EtosuccimmidePrimidoneSul:am

Lamotrigina10-OHcarbazepina/DHC

FenobarbitalCarbamazepinaepossido

OxaCarbazepinaStandardInternoCarbamazepina

Fenitoina


THERAPEUTICDRUGMONITORINGNEWAEDAn:epilep:cdrugs(UV/VIS)

THERAPEUTICDRUGMONITORINGNEWAEDAn:epilep:cdrugs(UV/VIS)

ELUITIONORDER

l Quicklyandsafetydetermina:onofLeve:racetaminserum/plasma.

l Leve:racetamisapromisingnewan:epilep:cdrug.Chemicallyitisunrelatedtotheexis:ngan:epilep:cdrugs.Sincethereisinter-individualdrugconcentra:onvariabilityinpa:ents,thedetermina:onofserumlevels(therapeu:cdrugmonitoring)canbeusefulinpa:entsdependingontheclinicalsesng.

THERAPEUTICDRUGMONITORINGLEVETIRACETAM(UV/VIS)

THERAPEUTICDRUGMONITORINGLEVETIRACETAM(UV/VIS)

THERAPEUTICDRUGMONITORINGVALPROICACID(UV/VIS)

l  Fordetermina:onofValproicacidinplasmaorserumbyHPLCsepara:on.

l Valproicacidisacarboxilicacidokenusedasan:convulsant.Ithasachainof8carbonatoms.

l Valproicacidisveryeffec:veinthetreatmentofepilepsy,otherusesincludetheprophylaxisandtreatmentofbipolardisorders.Thekitallowsthedetermina:onofvalproicacidinplasmaorserum.

THERAPEUTICDRUGMONITORINGVALPROICACID(UV/VIS)

OSTEOPOROSIS

l  CROSSLINKSPYD,DPD(FL)INURINESAMPLES,MARKERTODIAGNOSISOFOSTEOPOROSISANDRHEUMATOIDARTHRITIS

l  25-HYDROXYVITAMIND3/D2INPLASMASAMPLES(FL),VitaminDinsufficiencythereforeisassociatedwithmanychroniccondi:onsandlatencydiseases,aseveredeficiencyleadstorickets in children and osteomalacia in adults. This reagent kit allows the safechromatographic determina:on of 25-OH-Vitamin D3 on a simple isocra:c HPLC systemwithUVdetec:on.

l  HYDROXYPROLINE is an amino acid, which is an important marker in the diagnos:cs ofosteoporosis. Proline hydroxyla:on requires ascorbic acid. Themost obvious, first effects(gum and hair problems) of absence of ascorbic acid in humans come from the resul:ngdefectinhydroxyla:onofprolineresiduesofcollagen,withreducedstabilityofthecollagenmolecule causing scurvy. Aker a special sample prepara:on, hydroxyproline can bequan:fiedwithoutinterferencesasaderiva:ve.

CROSSLINKSPYD,DPD(FL)INURINESAMPLES,MARKERTODIAGNOSISOFOSTEOPOROSISANDRHEUMATOIDARTHRITIS

OSTEOPOROSISCROSSLINKSPYD,DPD(FL)

8

MANUALE DI PROPRIETA della Pharmaring S.r.l. NON PUO’ ESSERNE ASPORTATA O FOTOCOPIATA ALCUNA PARTE SENZA AUTORIZZAZIONE

CROMATOGRAMMI

standard di taratura

campione

OSTEOPOROSIS25-HYDROXYVITAMIND3/D2INPLASMA

The vitamin D exists in two different forms


l Vitamin D2 (ergocalciferol) isformed by the influence of sun -rays on its provitamin shape ofherbal(ergosterol)origin

•  Vitamin D3 (colecalciferol) isf o r m e d i n t h e s k i n b y7dehydrocholesterol with sun-rays


THECONCENTRATIONSOF25-HYDROXYVITAMIND3INPLASMACANBECORRELATEDAT:

l  BONEPATHOLOGIES

l  CARDIOVASCULARPATHOLOGIES

l  ACUTEANDCHRONICPNEUMOPATHIES

l  COGNITIVEDEFICIT

l  NEOPLASIAS(CANCER)

l  AUTOIMMUNEDESEASES

l  PULMONARYTUBERCULOSIS

l  Hydroxyproline is an amino acid content almost exclusively in collagen that is themaincons:tuent of bone and derma.? Hydroxyproline is a result of hydroxyla:on of prolineresidues, and once liberated from bone remodeling metabolic processes, it’s not morereusedforfurtherbiosynthe:cprocesses.

l  Forthisreasonthedosageofexpelledintheurineisconsideredasensi:vemeasureofthemetabolismofcollagen.Inurinehydroxyprolineispresentforthemostpartasadipep:de,tripep:de,andonlyinasmallamount(about3%)inthefreeform.

l  Duringadolescentage,duetointensegrowthofbone:ssue,theelimina:onofhydroxyprolineismuchhigherthaninadults.

OSTEOPOROSISHYDROXIPROLINE(FL)

OSTEOPOROSISHYDROXIPROLINE(FL)

7

MANUALE DI PROPRIETA della Pharmaring S.r.l. NON PUO’ ESSERNE ASPORTATA O FOTOCOPIATA ALCUNA PARTE SENZA AUTORIZZAZIONE

Aggiungere 1 mL dei campioni preparati come descritto nel paragrafo “TRATTAMENTO DEI CAMPIONI E DELLA SOLUZIONE DI RIFERIMENTO” Aprire i rubinetti e lasciare eluire. Al termine applicare un vuoto tale da eliminare tutto il liquido dalla fase stazionaria. Scartare questi eluati. Collocare sotto tutte le cartucce delle provette di polipropilene o vetro (evitare il polistirene). Aggiungere a tutte le cartucce 0,8 mL di Reagente D (cod. DKH-ISU-0108), utilizzare un vuoto tale da permettere una lenta eluizione . Al termine applicare un vuoto tale da eliminare tutto il liquido dalla fase stazionaria. Raccogliere questi eluati. Aggiungere a tutte le provette 100 µL del Reagente E (cod. DKH-ISU-0109). Passare all’analisi cromatografica. CONSERVAZIONE DEI CAMPIONI TRATTATI I campioni derivatizzati sono stabili almeno 24 h a +4 °C. CROMATOGRAMMI

CROMATOGRAMMA STANDARD DI CALIBRAZIONE ACQUISIZIONE DEI DATI ED ANALISI QUANTITATIVA Analisi quantitativa mediante standard La calibrazione avviene tramite l’iniezione dello standard di calibrazione. Per i calcoli le aree, o le altezze misurate sono normalizzate sullo standard interno.

l  T,T-MUCONICACID(UV/VIS)INURINESAMPLES,METABOLITESFROMTHEEXPOSURETOBENZENEANDDERIVATIVES

l  HIPPURICACID,METHYL-HIPPURICMANDELICACIDANDPHENYLGLYOXYLICACID(UV/VIS)INURINESAMPLES

l  CDTCARBOHYDRATE-DEFICIENTTRANSFERRIN(SERUM)(UV/VIS)

l  2,5-HEXANEDIONE(UV/VIS)INURINE

BIOMONITORINGESPOSITION

OCCUPATIONALMEDICINE

BIOMONITORINGT,T-MUCONICACID(UV)

l  T,T-Muconicacidisaminormetaboliteofbenzeneand,incombina@onwithphenol,isusedfortheassessmentofanoccupa@onalbenzeneexposure.

l  TheBiologicalExposureIndex(BEI)hasbeensetastheupperlimitforconcentra@onsoftoxicsubstancesandtheirmetabolitesinurinedefiningthemaximumconcentra@onsthatdonotnormallycompromiseaperson'shealth

BIOMONITORINGT,T-MUCONICACID(UV)

BIOMONITORINGHIPPURICACID,METHYL-HIPPURICMANDELICACIDANDPHENYL

GLYOXYLICACID(UV/VIS)

l  HIPPURIC ACID,METHYL-HIPPURICMANDELIC ACID AND PHENYL GLYOXYLIC ACID (UV/VIS) INURINESAMPLES;Hippuricacid,methylhippuricacid,arethemainmetabolitesoftolueneandmixtureofo-m-p,Xylene

l  MANDELIC ACID and PHENYLGLYOXYLIC ACID are the main metabolites of styrene,MANDELICACIDisthisevenasametaboliteofethylbenzene.

l  TheBiologicalExposureIndex(BEI)hasbeensetastheupperlimitforconcentra@onsoftoxicsubstancesandtheirmetabolitesinurinedefiningthemaximumconcentra@onsthatdonotnormallycompromiseaperson'shealth

AU

0,000

0,010

0,020

0,030

0,040

0,050

0,060

0,070

0,080

Minutes1,00 2,00 3,00 4,00 5,00 6,00 7,00 8,00 9,00 10,00 11,00 12,00 13,00 14,00 15,00 16,00 17,00 18,00 19,00 20,00

3,13

83,

456

3,75

7

4,47

74,

653

5,68

9 MA

- 6,0

39

6,59

3

7,57

8HA

- 7,

999

2-M

HA -

10,2

07

11,9

91

PGA

- 16,

041

4-M

HA -

18,7

05

3-M

HA -

19,8

05

BIOMONITORINGHIPPURICACID,METHYL-HIPPURICMANDELICACIDANDPHENYL

GLYOXYLICACID(UV/VIS)

l CDTCARBOHYDRATE-DEFICIENTTRANSFERRIN(SERUM)(UV/VIS),CDTDETERMINATIONREPRESENTSTHEMARKEROFALCOHOLABUSEFOREXCELLENCE,BOTHINTERMSOFSENSITIVITYTHATINTERMSOFSPECIFIC.

l  ABUSEOFALCOHOLICDRINKSMUSTBEREGARDEDASAPRIORITYISSUEOFPUBLICHEALTH,ITREPRESENTARISKFACTORFORTHEINDIVIDUALANDSOCIETY,WITHHEAVYIMPACTONTHEHEALTHANDSAFETYOFWORKERS.

BIOMONITORINGCDT(UV)

l CDT (UV/VIS); Compared to tradi:onal markers of chronic alcoholabuse (GGT, MCV, ALT and AST), the CDT has a higher specificity(around95%)and,notinsignificantfactor,isnotsubjecttovaria:onscausedbyotherdisordersasdrugs,diabetes,obesity, liverdisease,andhematologicaldisorders.


BIOMONITORING2,5-HEXANEDIONEINURINE(UV)

l  2,5-HEXANEDIONEINURINE(UV);N-HEXANEISANALIPHATICHYDROCARBONTHATISWIDELYUSEDASACONSTITUENTOFINDUSTRIALSOLVENTS,GLUES,PAINTS,INKSECC.ITISBIOTRANSFORMATEDBYOXIDASEINLIVERANDINSMALLERSIZEINOTHERTISSUE,THEMAINMETABOLITESEXCRECTEDINURINEARE2-HEXANOL,IL2,5-HEXANEDIONE,IL2-HEXANONEETC.

l  PROLONGEDEXPOSITIONLEADSPROGRESSIVEDAMAGETOSNP,DETERMININGAMOTORSENSITIVENEUROPATHY.2,5-HEXANEDIONEISTHEMAINTOXICMETABOLITEOFN-HEXANERESPONSIBLEOFTHESEINJURIES.

l  DETERMINATIONOF2,5-HEXANEDIONEINURINEISUSEDINBIOLOGICALMONITORINGEXPOSURETON-HEXANEINPROFESSIONALPEOPLEEXPOSED.

7. Valori di riferimento Soggetti non esposti inf. 1 mg/L Soggetti esposti inf. 5 mg/L 8. Disposizione dello scarico La fase mobile ed i campioni derivatizzati devono essere raccolti in apposito contenitore da dedicare allo stoccaggio di solventi organici privi di alogeni. 9. Cromatogrammi di esempio

9.1 Cromatogramma dello standard di calibrazione 9.2 Cromatogramma di un campione

AU

-0.004

-0.002

0.000

0.002

0.004

0.006

0.008

0.010

0.012

0.014

0.016

0.018

0.020

0.022

0.024

Minutes1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00

7.27

9

8.25

0

2,5-

esan

dion

e - 9

.483

12.6

92

AU

-0.004

-0.002

0.000

0.002

0.004

0.006

0.008

0.010

0.012

0.014

0.016

0.018

0.020

0.022

0.024

Minutes1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00

7.24

87.

536

8.19

98.

616

2,5-

esan

dion

e - 9

.446

11.2

79

12.6

87

14.6

17

VENDITA E ASSISTENZA TECNICA

APPARECCHIATURE SCIENTIFICHE E ANALITICHE ERRECI S.r.l.

CONCENTRATIONLOWERTHAN1mg/lOF2,5-ESANDIONEAREDETECTEDALSOINNON-EXPOSEDPEOPLES

BIOMONITORING2,5-HEXANEDIONEINURINE(UV)

VITAMINSPROFILEl  B6VITAMIN(FL)INSERUMSAMPLES,VitaminB6consistsofthreevitamers:pyridoxine,pyridoxaland

pyridoxamine.Themetabolicallyac:vecoenzymeformofvitaminB6ispyridoxal-5'-phosphate(PLP).DeficiencyofvitaminB6mainlyexpressinaltera:onsoftheskin,neurologicaldisordersandanemias.ThiskitallowstheanalysisofVitaminB6inserumsamples.

l  VITAMINA/E(UV/VIS)INSERUMSAMPLES,VitaminA(re:nol)isessen:alfortheforma:onofrhodopsin,forbonemetabolism,andforthesythesisofsteroidhormones.DeficiencyofvitaminAleadstonightblindness,dryskin,andlossofhair.VitaminE(α-Tocopherol),asapotentan:oxidant,protectsLDLcholesterolandcellularmembranesfromlipidperoxida:on,whichmainlyoccursasaresultofincreased.ThisKitallowsthesimultaneousanalysisofvitaminAandE.

l  VITAMINC(Plasma)(UV/VIS);DEFICIENCYINPOPULATIONLEADSINJURYOFAPARTICULARPATHOLOGICALCONDITION,THESCURVY.ITDETERMINESALSOASTENIA,ANEMIA,BONESALTERATIONS(OSTEOPOROSIS),DEPRESSION,ANEMYANDDIFFERENTRESISTANCETOINFECTIONS.

VITAMIN A / E (UV/VIS) IN SERUM SAMPLES,VITAMIN A AND 'ESSENTIAL TO FORM RHODOPSIN,HISLACKLEADSTOBLINDNESS'NIGHT,DRYSKINANDHAIRLOSS.

VITAMINPROFILEVITAMINA/E(UV/VIS)

VITAMINPROFILEVITAMINA/E(UV/VIS)

VITAMINB6(FL)INSERUMSAMPLES,DEFICIENCYOF VITAMIN B6 GIVES DERMAL ALTERATIONS,NEUROLOGICALDISORDERSANDANEMIA

VITAMINPROFILEVITAMINB6(FL)

COMPOSIZIONEIl Kit per la determinazione della Vitamina B6 in plasma prevede 100 determinazioni ed è composto da: Fase mobile, Standard di calibrazione, reagente A, reagente B, reagente C, e vials di reazione. Insieme ad ogni kit sono forniti il metodo analitico per la preparazi-one dei campioni ed il metodo per la ricostituzione dello standard di calibrazione indicante i valori di riferimento dello stesso

Diagnostic Division

srlSede: Via Meraviglia, 31 - 20020 Lainate (MI) - ITALIAtel: 02/93.25.88.99 - fax: 02/93.55.32.28www.pharmaring.it - [email protected]

A cir

cle around pharmaceutic

VITAMINA B6 Cod. (DKH-B6P-0100)

TRACCIATO CROMATOGRAFICO DELLO STANDARD DI TARATURA

PROCEDURAIn una provetta pipettare 250 µL di campione e 25 µL di reagente A,tappare, agitare sul vortex e centrifugare per 5 minuti.Dispensare nella vial di reazione 200 µL di sovranatante, 25 µL di reagente B e 25 µL di reagente C.Tappare, agitare sul vortex per alcuni secondi, aprire la vial per far sfiatare i gas, ritappare e scaldare per 20 minuti a 60°CIniettare 25 µL nel sistema HPLC.

KIT DISPONIBILI-

- Emoglobiniche patologiche - Emoglobina Glicata - Acido 5-Idrossiindolacetico - VMA (Acido Vanilmandelico) - Serotonina in campioni di urina - Serotonina in campioni di siero - Pyd, Dpd Crosslinks - Idrossiprolina - AED (Farmaci Antiepilettici) - Levetiracetam Zonisamide- 25-Idrossivitamina D3 - Amiodarone - Vitamina A/E - Omocisteina - Catecolamine in urina - Acido T,T Muconico - Catecolamine in plasma - Metanefrine - Vitamina B6 - Lamotrigina

For further information,please visit our web site:www.pharmaring.it

DiagnosticKits

MetodoFL

PLP = PIRIDOXALFOSFATO CP:09-0001-VITAMINA B6) PL = PIRIDOXALE

VITAMINPROFILEVITAMINB6(FL)

VITAMINSPROFILEVITAMINC(UV)PLASMA

Ascorbic Acid is a highly water-soluble natural vitamin. It’s is apowerful reducingagentthatplaysakeyrole inmanybiologicalprocesses; It has an:oxidant ac:vity since it can be reversiblyoxidized to Deidroascorbate.Man needs it in his diet, the dailyrequirementises:matedatabout50to100mg/day.DeficienceinVitaminCleadinmanpar:culardisease,thescurvy.Itleadsalsotoasthenia,anorexia,bonedisorders(osteoporosis),depression,anemiaanddecreasedresistancetoinfec:ons.

S A M P L E I N F O R M A T I O N

Acquired By: System Sample Name: 126477 Date Acquired: 22/12/2015 9.47.24 Sample Type: Unknown Acq. Method Set: ascorbico Vial: 51 Date Processed: 22/12/2015 9.54.47 Injection #: 1 Processing Method: ascorbico Injection Volume: 10,00 ulChannel Name: 2487Channel 1 Run Time: 10,0 MinutesProc. Chnl. Descr.: 260 Sample Set Name:

Auto-Scaled Chromatogram

AU

0,000

0,010

0,020

0,030

0,040

0,050

Minutes1,00 2,00 3,00 4,00 5,00 6,00 7,00

1,14

9

1,78

7

acid

o as

corb

ico -

2,11

7

2,62

12,

827

5,90

3

1

Name RT Area Height Amount Units

acido ascorbico 2,117 122617 20709 1,27 mg/dL

Peak Results

VITAMINSPROFILEVITAMINC(UV)PLASMA

NEWDEVELOPEDKITS

DYSBIOSISDIAGNOSIS

•  Skatoleinurinesamples(Dysbiosis)•  INDICANOinurinesamples(Dysbiosis)•  INDOLEinurinesamples(Dysbiosis)

INTESTINALPERMEABILITY•  MANNITOLinurinesamples•  LACTULOSEinurinesamples

DYSBIOSISTESTSKATOLEinUrineSamples

Disbiosisconsistsofanaltera:onofenzymesandbacterialflorathatlivewithinintes:ne,calledintes:nalmicrobiosisIftheSkatoleexceedsphysiologicallylevels,couldleadtoprobleminlargeintes:ne,especiallythecolon.

[min.]Time

0 1 2 3 4 5

[a.u.]

Inte

nsity

0

20

40

60

80

100

3.43

ska

tolo

1

s non dil skatolo_20_02_2017 10_15_16_004 - RF-20A: Channel 1s non dil add skatolo_20_02_2017 10_22_23_005 - RF-20A: Channel 1

Result Table (Uncal - s non dil add skatolo_20_02_2017 10_22_23_005 - RF-20A: Channel 1)

Reten. Time[min]

Area[a.u..s]

Height[a.u.]

Area[%]

Height[%]

W05[min]

CompoundName

Correction Factor

1 3.433 289.550 34.768 100.0 100.0 0.15 skatolo

Total 289.550 34.768 100.0 100.0

20/02/2017 10:34 Page 2 of 2Chromatogram C:\Clarity\5HIAA\Data\s non dil add skatolo_20_02_2017 10_22_23_005.PRM

DYSBIOSISTESTSKATOLEinUrineSamples

DYSBIOSISTESTINDICANOinUrineSamples

Disbiosisconsistsofanaltera:onofenzymesandbacterialflorathatlivewithinintes:ne,calledintes:nalmicrobiosis.If Indicano exceeds physiologically levels, could lead to problem insmallintes:ne.

DYSBIOSISTESTINDICANOinUrineSamples

[min.]Time

0 2 4 6 8 10

[a.u.]

Inte

nsity

0

20

40

60

80

100

120

140

2.40

1

3.08

2

3.65

3

4.18

4

4.45

5

5.62

6

6.23

7

7.93

8

8.77

9

9.47

1

0

10.0

2 in

dica

n 1

1

6_13_03_2017 11_50_26_009 - RF-20A: Channel 1

Result Table (ESTD - 6_13_03_2017 11_50_26_009 - RF-20A: Channel 1)

Reten. Time[min]

Area[a.u..s]

Amount[mg]

CompoundName

Correction Factor

11 10.017 1688.768 29.4 indican 1.000

Total 1688.768 29.4

14/03/2017 12:13 Page 2 of 2Chromatogram C:\Clarity\5HIAA\Data\6_13_03_2017 11_50_26_009.PRM

DYSBIOSISTESTINDOLEinUrineSamples

Disbiosisconsistsofanaltera:onofenzymesandbacterialflorathatlivewithinintes:ne,calledintes:nalmicrobiosis.If Indole exceeds physiologically levels, could lead to problem inintes:ne.

DYSBIOSISTESTINDOLEinUrineSamples

[min.]Time

0 2 4 6 8

[a.u.]

Inte

nsity

0

10

20

30

40

50

60

70

2.37

1

2.90

2

3.32

3

3.60

4

4.52

5

4.83

6

5.28

7

5.75

INDO

LO

8

6.08

9

6.73

1

0

7.23

1

1

8.65

1

2

ref indolo_20_03_2017 11_27_34_003 - RF-20A: Channel 1

Result Table (ESTD - ref indolo_20_03_2017 11_27_34_003 - RF-20A: Channel 1)

Reten. Time[min]

Area[a.u..s]

Amount[µg/L]

CompoundName

Correction Factor

8 5.750 128.925 0.5 INDOLO 1.000

Total 128.925 0.5

20/03/2017 12:14 Page 2 of 2Chromatogram C:\Clarity\5HIAA\Data\ref indolo_20_03_2017 11_27_34_003.PRM

MODULARHPLCSYSTEM

MODULEOFSYSTEM:•  HPLCPUMPISOCRATICORGRADIENT(UPTOQUATERNARY)•  UV/VISDETECTOR(Variablewavelength)(OPIONDOUBLEWAVELEBGTHORDAD)•  FLUORIMETRICDETECTOR(OTHERDETECTORAVAILABLE)•  COLUMNOVEN(UPTO6COLUMNS)WITHSELECTIONVALVE•  4CHANNELSON-LINEDEGASER•  AUTOSAMPLER(OPTIONTHERMOSTATIONAND/ORDERIVATIZZATION)•  COMPLETESOFTWARE•  DATASTATION•  REMOTETECHNICALASSISTANCEANDAPPLICATIVESUPPORT•  ERRECIASUNIQUEPARTNER(HPLCANDKIT)•  SEVERALPURCHASEFORMULA

MODULARHPLCSYSTEM

•  DEVELOPMENTOFCUSTOMMETHOD•  TECHNICALSERVICEANDAPPLICATIONSUPPORTTOADDNEWPARAMETERS

•  TECHNICALSERVICE• WORKSHOP

MOREOVER

ERRECIS.r.l.ViadelleRobinie,2120090–OPERA(MI)T.+39/02/57600456Fax+39/02/57600082e-mail:[email protected]

STRUMENTAZIONE SCIENTIFICA E ANALITICA

VENDITA E ASSISTENZA TECNICA

www.erreci-tech.it

ERRECI

hplc ready to use diagnostic kit for hplc

Documents